← Human Trials & Peer-Reviewed Studies
A Randomized, Controlled Study to Assess Biomarkers of Exposure in Adult Smokers Switching to Oral Nicotine Products.
Plain-language guide to PMID 35730535 (2022): open-label randomized controlled trial of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 35730535
- Journal
- Journal of clinical pharmacology
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Edmiston J et al. (4 authors)
- DOI
- 10.1002/jcph.2098
What This Study Did, in Plain Language
What Was Tested
Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.
The primary objective compared 24-hour urinary total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL; a biomarker for the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) in dual and exclusive use of discs and chews to continue smoking and NT on day 7.
Why It Was Studied
This open-label, randomized, controlled, in-clinic, 6-parallel-group study evaluated changes in biomarkers of exposure (BoEs) to select harmful and potentially harmful constituents in adult smokers (N = 213) not planning to quit smoking.
Who Took Part
The age groups tagged for this paper are adults.
How the Study Was Run
In design terms this was a randomized, open-label and parallel-group study.
Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.
Being open-label, the Therapeutic nicotine (patch, non-peptide) study did not mask who received what.
The Therapeutic nicotine (patch, non-peptide) group and the comparison group ran side by side rather than switching.
What Was Measured
This open-label, randomized, controlled, in-clinic, 6-parallel-group study evaluated changes in biomarkers of exposure (BoEs) to select harmful and potentially harmful constituents in adult smokers (N = 213) not planning to quit smoking.
PubMed files the paper under topics including Biomarkers, Carcinogens, Electronic Nicotine Delivery Systems, Nicotine and Smokers.
The authors tagged it with the keywords NNAL, adult smokers, biomarkers of exposure, oral nicotine and oral tobacco-derived nicotine products.
What This Means in Plain Language
The paper is a randomized, open-label and parallel-group study of Therapeutic nicotine (patch, non-peptide).
The publication is from 2022 (Journal of clinical pharmacology), a journal based in England.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.